Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-10-31
Target enrollment:
Participant gender:
Summary
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.